Corvus Pharmaceuticals reports clinical, financing, governance, and financial updates for a clinical-stage biopharmaceutical company developing ITK inhibition as an immunotherapy approach for immune diseases and cancer. Its lead candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit interleukin-2-inducible T cell kinase, a protein involved in T cell activation, signaling, differentiation, and function.
Recurring company news centers on soquelitinib clinical development in relapsed/refractory peripheral T cell lymphoma and atopic dermatitis, including immunologic and biomarker data presented at medical meetings. Updates also cover business results, public equity financing for research and development, board composition, and other clinical-stage pipeline disclosures.
Corvus Pharmaceuticals (NASDAQ: CRVS) announced the publication of preclinical data in Science Signaling, demonstrating the potential of ITK inhibition with soquelitinib for treating inflammatory diseases. The study, conducted by Cornell University researchers, showed that ITK inhibition induces switching of proinflammatory Th17 cells into anti-inflammatory Treg cells, both in vitro and in vivo.
Key findings include:
- Dose-dependent inhibition of Th17 cell differentiation and increase in Foxp3+ Treg cells
- Switched Foxp3+ Treg cells suppress naïve T cell proliferation
- Significant reduction of Th17 cells in the lung in a mouse model of allergic airway inflammation
This research supports Corvus' view on the broad potential of ITK inhibition for treating autoimmune, allergic, and inflammatory diseases.
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker CRVS, has announced that it will participate in the Jefferies Global Health Conference in New York from June 5-7, 2024. The company's CEO, Richard A. Miller, and Chief Business Officer, Jeffrey Arcara, will present a corporate overview and conduct one-on-one meetings with investors. The presentation is scheduled for June 5 at 3:00 pm ET and will be webcast live, with the recording available for 90 days on the company's investor relations webpage.
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company, reported strong progress in advancing soquelitinib for PTCL and generating early data for atopic dermatitis. Recent financing provided runway for expected clinical readouts in 2024-2025. Positive Phase 1 trial results for ciforadenant in renal cell cancer. Corvus also collaborates with Kidney Cancer Research Consortium and Angel Pharmaceuticals. Financially, Corvus reported cash, cash equivalents, and marketable securities of $22.1 million as of March 31, 2024, with expected full year 2024 net cash used in operating activities between $24-27 million.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) will provide a business update and report first quarter 2024 financial results on May 6, 2024. The company will host a conference call and webcast at 4:30 pm ET / 1:30 pm PT. Investors can access the call through dial-in numbers or the webcast link. A replay will be available on the company's website.
Corvus Pharmaceuticals has announced a $30.6 million registered direct offering to raise gross proceeds through the sale of common stock and warrants. The offering includes participation from various healthcare investors and existing investors, with the company's CEO also joining. The offering is expected to close on May 6, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.